(Bloomberg) — Watson, an artificial intelligence technology that IBM wants to sell to help doctors diagnose diseases, will largely escape the oversight of regulators if the computer giant wins a two-year Washington lobbying push.

International Business Machines Corp.'s argument to Congress is that its supercomputer, famed for victory on quiz show "Jeopardy!," isn't a medical device like a cardiac pacemaker and shouldn't need lengthy clinical trials to prove it's safe and effective. A draft bill released Tuesday backs that position, and could speed the use of Watson and other so- called decision support technologies.

The artificial intelligence technology already has medical fans. Eric Topol, a genomics professor at the Scripps Research Institute, has used Watson to find research subjects who have serious conditions never before identified. When Watson diagnoses someone — like it did with a patient with plastic lung, a rare condition that restricts airflow — Topol can scratch them off his list of candidates.

Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.

  • Critical BenefitsPRO information including cutting edge post-reform success strategies, access to educational webcasts and videos, resources from industry leaders, and informative Newsletters.
  • Exclusive discounts on ALM, BenefitsPRO magazine and BenefitsPRO.com events
  • Access to other award-winning ALM websites including ThinkAdvisor.com and Law.com

© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.